Results 21 to 30 of about 95,577 (390)
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Science, 2019 The dope on l-dopa metabolism The efficacy of l-dopa treatment for Parkinson's disease is hugely variable between individuals, depending on the composition of their microbiota.
Vayu Maini Rekdal +4 more
semanticscholar +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
Experience in using levodopa-benserazide
Неврология, нейропсихиатрия, психосоматика, 2015 Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina +3 more
doaj +1 more source
Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes
Frontiers in Neurology, 2021 Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li +7 more
doaj +1 more source
Nature Communications, 2019 Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria in their ability to decarboxylate levodopa to dopamine
Sebastiaan P. van Kessel +6 more
semanticscholar +1 more source
New advances in amblyopia therapy I: Binocular therapies and pharmacologic augmentation [PDF]
, 2018 Amblyopia therapy options have traditionally been limited to penalisation of the non-amblyopic eye with either patching or pharmaceutical penalisation. Solid evidence, mostly from the Pediatric Eye Disease Investigator Group, has validated both number of
Culican, Susan M, Kraus, Courtney L
core +2 more sources
ACS Sensors, 2019 Levodopa is the most effective medication for treating Parkinson's disease (PD). However, because dose optimization is currently based on patients' report of symptoms, which are difficult for patients to describe, the management of PD is challenging.
K. Y. Goud +6 more
semanticscholar +1 more source
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]
, 2003 Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P. +11 more
core +4 more sources
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease
New England Journal of Medicine, 2019 BACKGROUND Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease‐modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be ...
C. V. Verschuur +13 more
semanticscholar +1 more source